ESLA Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in A
ESLA Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Story updates
12:01:27 PM UTC
SquawkNews
ESLA - Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
ESLA - Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma